Condition
Hepatic Cell Carcinoma
Total Trials
5
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (2)
Trial Status
Unknown3
Recruiting2
Clinical Trials (5)
Showing 5 of 5 trials
NCT06515314Phase 1RecruitingPrimary
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
NCT06265272Recruiting
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
NCT06144385Phase 1Unknown
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
NCT06042842UnknownPrimary
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC
NCT04048317Early Phase 1UnknownPrimary
Effectiveness of Drug Eluting TACE in Primary HCC
Showing all 5 trials